Showing results (171-180 of 182) with videos related to

Sort By:
Pageof 19
Journal of Neuroendocrinology|May 16, 2024
Clinical management of typical and atypical carcinoids/neuroendocrine tumors in ENETS centres of excellence (CoE): Survey from the ENETS lung NET task forceAnna Koumarianou, Pier Luigi Filosso, Lisa Bodei, et al.
Clinical Nuclear Medicine|May 4, 2022
ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE TherapyCharito Love, Neil B Desai, Tony Abraham, et al.
Medrxiv : the Preprint Server for Health Sciences|July 16, 2025
Delta-like ligand 3 expression and functional imaging in gastroenteropancreatic neuroendocrine neoplasmsRohit Thummalapalli, Salomon Tendler, Joanne F Chou, et al.
JCO Precision Oncology|November 20, 2025
Delta-Like Ligand 3 Expression and Functional Imaging in Gastroenteropancreatic Neuroendocrine NeoplasmsRohit Thummalapalli, Salomon Tendler, Joanne F Chou, et al.
European Journal of Cancer (Oxford, England : 1990)|February 15, 2021
Consensus on molecular imaging and theranostics in neuroendocrine neoplasmsValentina Ambrosini, Jolanta Kunikowska, Eric Baudin, et al.
Endocrine Connections|September 2, 2016
A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease managementKjell Oberg, Eric Krenning, Anders Sundin, et al.
Journal of the National Cancer Institute|May 31, 2023
Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meetingSimron Singh, Thomas A Hope, Emily B Bergsland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2025
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline UpdateRohan Garje, Irbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 29, 2023
Joint EANM/SNMMI procedure guideline for the use of <sup>177</sup>Lu-labeled PSMA-targeted radioligand-therapy (<sup>177</sup>Lu-PSMA-RLT)Clemens Kratochwil, Wolfgang P Fendler, Matthias Eiber, et al.
The Lancet. Oncology|July 3, 2026
Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS)Christophe M Deroose, Hannes Leupe, Rodney J Hicks, et al.
Pageof 19